GlassScriptPhysician profile
Doug J Sposetta
NPI 1598131237
$17,350.86
in general payments reported to CMS, 2019-2025
52 companies · $3,540 in 2025
The $3,540 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,495 · 2022: $3,345 · 2023: $3,623 · 2024: $3,347 · 2025: $3,540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $217.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,293.36 |
| Education | $216.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,223.43 | 2021-2025 | |
| Novo Nordisk INC | $1,539.64 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,367.02 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,320.61 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,302.00 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,077.33 | 2021-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $784.50 | 2021-2025 | Synjardy, Jardiance, Spiriva Respimat |
| Otsuka America Pharmaceutical, INC. | $685.56 | 2021-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $562.43 | 2021-2025 | Xifaxan, Trulance |
| Amarin Pharma, INC. | $539.85 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $515.76 | 2021-2025 | Verquvo, Belsomra, Steglatro |
| Astellas Pharma US INC | $460.34 | 2021-2025 | Veozah |
| Glaxosmithkline, LLC. | $452.05 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $426.72 | 2021-2024 | Xarelto |
| Almatica Pharma LLC | $404.08 | 2021-2025 | Loreev Xr, Sertraline Hcl, Gralise |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Doug Sposetta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.